ʻO ka Metglib kahi lāʻau lapaʻau hoʻohui hoʻohui me ka hopena hypoglycemic, i hoʻolālāʻia e kāohi i ka maʻi diabetes 2 ʻano. Hoʻomaopopo ka lāʻau antidiabetic o ka lāʻau o ka koho mua e ʻelua mau ʻano lāʻau me ke ʻano hoʻohui o ka hana, e hiki ai i ka mana ikaika o ka metabolism ka insulin a me ka glucagon. Hoʻohana ʻia ka lāʻau lapaʻau no ka poʻe maʻi maʻi e hui pū i ka lawe ʻana i nā papa me ka insulin: e hōʻemi ana lākou i ka huehue a me ka helu o nā inikini hormone.
ʻOiaʻiʻo, ʻaʻole kūpono ke hoʻohana ʻia i nā hihia a pau (e like me kekahi lāʻau lapaʻau hypoglycemic), akā pili pololei ʻo Metglib me nā mana o kēia wā o ka pilina a me ka maikaʻi.
ʻO ka hiʻohiʻona o ka lāʻau lapaʻau
A hoʻāʻo ʻia ka noʻonoʻo maikaʻi maikaʻi a i ka hoʻoliʻi maikaʻi ʻana i ʻelua mau mea ikaika - metformin (400-500 mg) a me glibenclamide (2.5 mg) hiki i ka hoʻopohapiha a ʻike piha i ka ʻike glycemic, akā hiki nō iā ia ke hōʻemi i ka pae ʻana o nā mea kanu.
Ke hoʻohana ʻia kēlā me kēia lāʻau lapaʻau maʻamau i ka monotherapy, ʻokoʻa loa kā lākou dosis. Hoʻohui kekahi i nā mea maʻamau, loaʻa pū nā hoʻopihapiha i ke ʻano o cellulose, starch, gelatin, glycerin, talc a me nā mea hoʻohui'ē aʻe. Kahi ʻia nā papa ʻaʻai Metglib i loko o kahi waihona ʻaiʻu no ka 5 mg glibenclamide a me 500 mg metformin.
Hiki ke hoʻomaopopo ʻia kahi lāʻau lapaʻau paʻakikī e nā ʻanolala i lalo: nā papa oval i ka pale pale o ka terracotta a i ʻole ke waiho ʻulaʻula keʻokeʻo me ka laina hoʻokaʻawale i nā ʻāpana o nā pūpū o 10 - 90 mau ʻāpana. Hoʻopili ʻia nā poli me nā kauoha ma kahi pahu pahu. Ma ke kumu kūʻai kūpono Metglib: 240-360 mau rubles. no ka pahee.
Lapaʻau Metglib
ʻO ka mea kumu mua o ka hopena i ʻike ʻia ka hapanui o nā maʻi me ka maʻi 2 like me ka metformin, ʻo ia wale nō ke ʻano o kāna ʻano i ka pūʻulu biguanide e hōʻemi ana i ka pale ʻana o nā ʻenekela i hoʻopau ʻia i ka insulin endogenous. ʻOi aku ka maikaʻi o ka hoʻololi ʻana ma mua o ka hoʻoulu ʻana o kāna hana, ʻoiai ke ʻano o ka maʻi type kīkē 2, ʻo nā cells-cells e hāʻawi i ka nui o ka hana.
Ma kahi o ka hoʻomaikaʻi ʻana i ka pono o ka postreceptor insulin, ʻo ia hoʻi ka pono o ka māhele.
- Hoʻopili i ka hoʻopili ʻana o ka glucose i nā pā o ka puʻuwai, hoʻoulu ʻia i kona hoʻohana e nā ʻili;
- Inhibition o ka gluconeogenesis;
- Ka pale o β-cell mai ka mua apaptosis a me nā nekrosis;
- Ke kāohi ʻana i nā āpau o ka acidosis a me nā maʻi koʻikoʻi;
- ʻO ka hoʻokalakupua o ka microcirculation o nā wai ola, endothelial function a me lipid metabolism;
- Hōʻemi i ka hoʻoliʻiliʻi koko, ke kāohi ʻana i ke kaumaha o oxidative, hoʻomaikaʻi i ke ʻano o ka lipid koko.
ʻO ke kūlana koʻikoʻi no ka maʻamau o ka hoʻopili ʻana o ka lipid type i ke ʻano type diabetes 2. Kōkua ʻo Metformin i ka pale ʻana i ka maʻi hānai. ^ E Ha yM. Ma kahi maʻi hōʻeha e hoʻonui ai i nā maʻi o nā maʻi maʻi o ka hōʻemi i ka 40%. Hoʻopiliʻo Biagunide i nā loli loli. ʻOi aku ka poʻe olakino ma mua o 40 mau makahiki, ʻāpono ʻo WHO i ka hoʻohana ʻana i ka Metformin ma ka palena liʻiliʻi loa e pale aku ai i ka ʻelemakule a me nā hanana cardiovascular.
ʻO ka mea kanu manamana ʻelua, ʻo ia ka glibenclamide, he ʻelele o ka hui hou ʻana o ka lāʻau sulfonylurea.
Hoʻokomo ʻia ka lāʻau lāʻau i ka papa inoa o nā lāʻau nui me nā hopena pancreatic a me nā extrapancreatic effects.
Ke hoʻouluʻana i ka pancreas, hoʻonui ka mea hoʻomehana i ka hana o kāna iho insulin. E pili ana i nā kuleana β-kuleana no ka holomua o ka ʻōpiopio type 2, he kūleʻa ka glibenclamide a mālama i kā lākou hana ma o ka hoʻoulu ʻana i nā receptors o nā cell insensitive target.
Pono ʻia ka lāʻau paʻakikī i nā manawa āpau o ka hoʻomohala ʻana i ka maʻi maʻi, no ka mea, e hāʻawi ana i ka hopena multivariate:
- Pancreatic - hoʻonui i ka ʻike o nā ʻenehana target, pale i nā seleka β mai nā glucose kūwaho, e hoʻoulu ai i ka synthesis o ka insulin;
- ʻO ka extra-pancreatic - hana pololei ka metabolite me nā ʻōpū a me nā momona, ʻae i ka glucogenesis, a hiki i ka glucose ke hoʻopili piha.
ʻO ka hapa kūpono o nā mea kanu o ka ʻaʻoma e ʻae iā ʻoe e hoʻoponopono i ke ʻano ma ka liʻiliʻi, hoʻonui i ka palekana o ka lāʻau lapaʻau, e hōʻemi ana i ka hōʻemi o nā ʻaoʻao a me nā hana kūpono.
ʻO ka Pharmacokinetics o ka lāʻau
Hoʻomili ʻia ka metformin i ka pūnao ʻana me ka wikiwiki, ke kahele ʻia me ka wikiwiki kiʻekiʻe ma ke kino holoʻokoʻa, ʻaʻole i launa pū me nā kō koko. Aia kona bioavailability e pili ana i ka 50-60%.
ʻAʻole ʻike ʻia nā mea momona Metformin i loko o ke kino; ʻaʻole i loli, e pau ʻia e nā pūpū a me nā ʻawaʻawa. ʻO ka hapalua ola he 10 mau hola, ua ʻike ʻia ka nui o ke koko ka nui o 1-2 mau hola ma hope o ka lawelawe waha o ka lāʻau.
Hoʻopili ʻia ʻo Glybenclamide mai ka gastrointestinal tract a hoʻoili ʻia e ka 84%, ʻo ka pihi o kona neʻī ʻana e like me ka metformin. Hāpai nā protein koko i ka lāʻau lapaʻau ma 97%.
ʻO ka loli o ka glibenclamide i loko o ka mōʻīpī inert e hele i loko o ka ate. Ma kahi o ka hapalua o nā huahana pala e hoʻopili ʻia e nā ʻōpū, ʻo ke koena kahi o nā bile dile. ʻO ka hoʻopau hapa hapa-ola he maʻamau me ka metformin.
Nā Hōʻike
Ua kuhikuhi ʻia ʻo Metglib a me Metglib Force no ka maʻi type 2, inā he loli ʻano ke ʻano a me ka mālama mua ʻana me ka metformin a i ʻole ka hoʻohālikelike ʻana o ka hui monopreparations o ka metropin a i ʻole ka ʻae ʻia o ka monopreparations group. Hoʻomaopopo ʻia e hoʻololi i ka lāʻau lapaʻau me nā lāʻau metformin a me ka sulfonylurea me kahi lāʻau paʻakikī me ka loaʻaʻole o ka hoʻomau mau i nā hōʻailona glycemic i mea e hōʻemi ai i ka waʻa o nā lāʻau lapaʻau a me nā ukana ma ke kino. Ua kūpono hoʻi nā pāola a me nā maʻi diabetes-hilinaʻi me ka maʻi type 2.
Nā Hoʻohui
Hoʻonui ka hopena hui i ka nui o nā contraindications, ʻoiai i ka laulā nui o nā hua o ka pulu hoʻomalu no ka palekana a me ka pono ua hoʻāʻo ʻia e ka manawa. Mai kuhikuhi i Metglib:
- ʻO nā mea maʻi me ka hypersensitivity i kekahi mau o ka ʻano;
- ʻO nā poʻe me nā gestational a me nā ʻano maʻi maʻi maʻi 1st;
- Hoʻopilikia ia e ka maʻi maʻi mika a i ʻole nā palena palena;
- ʻO nā mea maʻi me ka mōʻaukala o nā hana hana kūpono o nā aʻeha a me nā moliki paha;
- Inā i ka helu ʻana, ua hoʻonui ʻia ka creatinine i 110 mmol / l i nā wahine a me 135 mmol / l i nā kāne;
- Me ka hypoxia o nā ʻano kumu;
- ʻO ka poʻe maʻi e hōʻike ana me ka lactic a me ketoacidosis;
- ʻO ka maʻi kuʻuna me ka hypoglycemia i hōʻeha ʻia e nā maʻi metabolic;
- Nūhou - i ka manawa o nā hōʻeha koʻikoʻi, nā maʻi, ka wela, ka gangrene;
- I ka manawa conservative therapy;
- Me ka leukopenia, porphyria;
- Inā aia ka mea maʻi i kahi meaʻai pōloli, ʻike ka calorie kahi i kū ʻole ma mua o 100 kcal / lā ;;
- Me ka inu waiʻona (hoʻokahi a maʻi ʻole paha).
No nā kamaliʻi, nā makuahine hāpai a me ka lactating, ʻaʻohe kumu hōʻike e pili ana i ka pono a me ka palekana o ka mālama ʻana, no laila ua kipi pū ʻia hoʻi ʻo Metglib ma kēia ʻano o nā maʻi.
ʻLoe a me ke kākele
Ke koho nei i kahi mahele, ke kau nei ke kauka i nā hopena o nā hōʻike, ke ʻano o ka maʻi, nā ala kūpono, nā makahiki o ka maʻi maʻi a me ka pane ʻana aku o ke kino i nā mea o ka lāʻau lapaʻau.
No ka Metglib Force, e like me nā kauoha no ka hoʻohana ʻana, ʻo ka nui o ka lā mua o kēlā me kēia lā he 2.5 / 500 mg a i ʻole 5/500 mg hoʻokahi. Inā lilo kekahi o nā ʻāpana Metglib a i ʻole nā analogues o ke kaʻina sulfonylurea i hoʻohanaʻia ma ke ʻano he lāʻau mua, a laila i ka wā e hoʻohuli ai i ka lāʻau me ka hoʻohui pū ʻana, e alakaʻi ʻia ana lākou e ka dosage o nā papa mua.
Pono ka neʻe ʻana o ka titration: ma hope o 2 hebedoma, hiki iā ʻoe ke loiloi i ka hopena o ke ʻano o ka hopena therapeutic mua a hoʻoponopono iā ia i 5/500 mg. Me kahi papa o ka hapalua mahina, inā pono, hiki ke hoʻonui ʻia ke ʻano iā 4 papa i ka papaʻaʻai o 5/500 mg a i nā papa papa 6 me kahi pākaʻi o 2.5 / 500 mg. No ka Metglib me kahi pākaukau o 2.5 / 500 mg, ʻo ka nui loa he 2 mg o ka lāʻau.
Hoʻolako maikaʻi ʻia ka papa inoa dosage ma ka papa ʻaina.
| Hōʻailona kii | Ka helu o nā paila | Nā hiʻohiʻona o ka hoʻokipa ʻana |
| 2.5 / 500 mg a me 5/500 mg | Loikau 1 pc 2-4 mau pcs. | i ke kakahiaka me ka ʻaina kakahiaka; kakahiaka a me ke ahiahi, me ka ai |
| 2,5 / 500 mg | 3,5,6 pcs | 3 mau rubles i ka lā, me ka ʻaina kakahiaka, ka ʻaina awakea, ka ʻaina |
| 5/500 mg | 3 pcs | 3 mau rubles i ka lā, me ka ʻaina kakahiaka, ka ʻaina awakea, ka ʻaina |
| 2,5 / 400 mg | mai 2 pcs. | kakahiaka a me ke ahiahi, i kekahi manawa |
No nā maʻi maʻi maʻi me ka liʻiliʻi o ka hiki ʻana i nā puʻupuʻu liʻiliʻi, ua kuhikuhi mua ʻia ka nui o ka lāʻau o ka Metglib Force me ka 2.5 / 500 mg. I kēia hihia, pono e nānā mau ʻia ke kūlana o ka ʻōpū, ʻo ka hōʻuluʻulu ʻana o ka metformin i kona wā hoʻopau ʻole he mea paʻakikī ia, akā he hoʻopiʻi koʻikoʻi - kahi lactic acidosis. Me ka hoʻoikaika kino kino loa a me ka ʻai kīnā ʻole, ua like nā palena.
ʻO nā hopena hemo, overdose
ʻAʻole nā kumu i ke kumu e hōʻole i ka mālama ʻana: ma hope o ke ʻano o ke kino, hele a nui nā hōʻailona like me lākou iho, a ʻoi aku ka nui o ka hōʻeha ʻana mai ka maʻi maʻi ʻole e ʻike ʻia ma mua o ka hopena e hiki mai ana ma Metglib. ʻO ka mea nui ka helu pololei ʻana i ka dosage: me ka mea ʻole a nānā ʻia paha i hoʻolālā ʻia, ka maʻi maʻi maʻi maʻi e hoʻomōhala i ka makemake a ka wolf, nalowale ka ikaika, hopohopo nā lima, lulu nā lima. Pehu a ua keʻokeʻo ka paʻu, wikiwiki ka ʻōpū o ka puʻuwai, kokoke i nā mea palupalu. No ka loaʻa ʻana o ka hypoglycemia i ʻoi aku ka poʻe no ka poʻe ʻelemakule a nawaliwali ʻia e ka maʻi a me ka hypocaloric i kūlohelo i nā maʻi maʻi.
Ma ke ʻano o ka nui o ka makehe, ʻike ʻia nā mea penei:
- ʻEha ka ʻōpū
- Migraines
- Nā maʻi Dyspeptic;
- Nā ʻano like ʻole o ke ʻano maʻi.
Hoʻokuʻu ʻia ka ʻoluʻolu hōʻoluʻolu kino i ka wā maʻi, ke hōʻike mau nei i ka hōʻailona me ka pono o nā analogie Metglib - Diabeton, Dimaril, Gluconorm, Bagomet Plus, Glukovans, Glibenclamide i hui pū me Metformin, Glucofast (ma ka ʻaha o ke kauka).
Na maʻi maʻi e pili ana i ka Metglieb
Ma nā papa kūkala kūkākūkā ma Metglib, ua hui pū ʻia nā loiloi o nā maʻi maʻi a me nā kauka, no ka mea ʻo ka hapanui o nā maʻi e hoʻomaʻamaʻa nei i ka paʻakikī, a ua paʻakikī iā lākou e loiloi i ka hopena o kekahi lāʻau lapaʻau ponoʻī. ʻO nā ʻike hou aku e pili ana i ka hoʻoponopono hou ʻana: ʻo nā mea a lākou i koho ai ke koho ʻana, ʻaʻole lākou e hoʻopiʻi pono i nā hopena ʻokoʻa. Akā ʻo ka hoʻāʻo ʻana i ka ʻike ma kahi maʻi maʻi kīnā ʻole he mea kūpono ʻole a he pōʻino wale nō.
I ka hōʻuluʻulu ʻana o nā manaʻo āpau, hiki iā mākou ke hoʻopau i ka Metglib no ka monotherapy o nā maʻi maʻi type 2 ʻo ia ka mea maikaʻi loa: kahi palekana palekana palekana a me ka hopena kūpono, ke kumukūʻai kūpono, hopena maikaʻi i ke kaumaha o ka mea maʻi, pale i nā pilikia cardiovascular a me ka oncological i kau i ka lāʻau lapaʻau i kahi ʻano hanohano o nā lāʻau koho mua-koho.
